Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
The poor prognostic OC patient subgroup, may have an extension of PFS from treatment intensification with atezolizumab added to frontline chemotherapy-bevacizumab regimen. This hypothesis-generating outcome warrants further understanding on the added role of ICI in the frontline setting.
Authors
- Alla Lisyanskaya (ORCID: https://orcid.org/0000-0002-4495-9681)
- Lyndsay Willmott (ORCID: https://orcid.org/0009-0007-8004-2559)
- Charles Landen
- Aurore Carrot (ORCID: https://orcid.org/0000-0002-8835-2865)
- Maria Elena Laudani (ORCID: https://orcid.org/0000-0003-2865-7939)
- Charles Anderson (ORCID: https://orcid.org/0000-0001-9226-107X)
- Roberto Hegg (ORCID: https://orcid.org/0000-0002-6453-8155)
- Florian Heitz (ORCID: https://orcid.org/0000-0002-2412-0352)
- Sudarshan Sharma (ORCID: https://orcid.org/0009-0004-0949-4577)
- Tashanna Myers (ORCID: https://orcid.org/0000-0002-4770-1408)
- Premal H. Thaker (ORCID: https://orcid.org/0000-0002-0568-6959)
- Stephanie V. Blank (ORCID: https://orcid.org/0000-0002-5333-9484)
- Sabrina Chiara Cecere (ORCID: https://orcid.org/0000-0002-7915-1623)
- Carol Aghajanian (ORCID: https://orcid.org/0000-0003-0851-3225)
- Jesús Alarcón
- Yvonne G. Lin (ORCID: https://orcid.org/0000-0002-0888-7182)
- Fatih Selçukbırıcık (ORCID: https://orcid.org/0000-0002-1273-1674)
- Kathleen N. Moore (ORCID: https://orcid.org/0000-0002-5803-0718)
- Benoît You (ORCID: https://orcid.org/0000-0002-3177-8857)
- Mayu Yunokawa (ORCID: https://orcid.org/0000-0001-7354-6977)
- Yvette He
- Josefin Fernebro
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Karolinska University Hospital (SE)
- Baystate Medical Center (US)
- Koç University (TR)
- PAREXEL International (United Kingdom) (GB)
- Université de Lyon (FR)
- Washington University in St. Louis (US)
- University of Alabama at Birmingham (US)
- University of Chicago (US)
- Hospices Civils de Lyon (FR)
- City Clinical Oncology Center (RU)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Kliniken Essen-Mitte (DE)
- Willamette Valley Cancer Institute and Research Center (US)
- Ping (United States) (US)
- Hospital Universitario Son Espases (ES)
- Centro de Pesquisas Oncológicas (BR)
- Japanese Foundation For Cancer Research (JP)
- University of Oklahoma Health Sciences Center (US)
- University of Turin (IT)
- La Roche College (US)
- Charité - Universitätsmedizin Berlin (DE)
- HCL Technologies (India) (IN)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1016/j.ygyno.2025.04.577
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- F. Hoffmann-La Roche
- Université Claude Bernard Lyon 1